everolimus

Ligand id: 5889

Name: everolimus

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: everolimus

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 15
Hydrogen bond donors 3
Rotatable bonds 9
Topological polar surface area 204.66
Molecular weight 957.58
XLogP 4.13
No. Lipinski's rules broken 1

Molecular properties generated using the CDK

Classification
Compound class Synthetic organic
Approved drug? Yes (FDA & EMA (2009))
International Nonproprietary Names
INN number INN
7863 everolimus
Synonyms
Afinitor® | Certican® | RAD-001 | RAD001 | rapamycin, 42-O-(2-hydroxyethyl)- | Zortress®
Database Links
CAS Registry No. 159351-69-6 (source: SciFinder)
ChEMBL Ligand CHEMBL1908360
DrugBank Ligand DB01590
GtoPdb PubChem SID 178102512
PubChem CID 6442177
Search Google for chemical match using the InChIKey HKVAMNSJSFKALM-GKUWKFKPSA-N
Search Google for chemicals with the same backbone HKVAMNSJSFKALM
Search PubMed clinical trials everolimus
Search PubMed titles everolimus
Search PubMed titles/abstracts everolimus
Search UniChem for chemical match using the InChIKey HKVAMNSJSFKALM-GKUWKFKPSA-N
Search UniChem for chemicals with the same backbone HKVAMNSJSFKALM
Wikipedia Everolimus
Comments
Everolimus is a Type-3 kinase inhibitor and was first approved by the FDA in 2009. There is some ambiguity in the literature as to the exact stereochemistry of everolimus. The structure shown here matches that in the Pubchem entry linked to above. Other common representations include CID 46930999, CID 70789204 and CID 16211121.